ScienceLatest
Novo's Subscription Model Raises Pharma-Telehealth Questions
Novo's new subscription model for telehealth services is stirring debate in the pharmaceutical industry. Experts are questioning the implications of this approach for patient access and healthcare costs.
0 upvotes
What happened
Novo's new subscription model for telehealth services is stirring debate in the pharmaceutical industry.
Why it matters
Experts are questioning the implications of this approach for patient access and healthcare costs.